Skip to main content
Erschienen in: Journal of Neurology 2/2015

01.02.2015 | Original Communication

Natural history of skeletal muscle involvement in myotonic dystrophy type 1: a retrospective study in 204 cases

verfasst von: Jean-Pierre Bouchard, Louise Cossette, Guillaume Bassez, Jack Puymirat

Erschienen in: Journal of Neurology | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Myotonic dystrophy type 1 (DM1) is the most frequent muscular dystrophy in adult. The aim of this study was to investigate the natural history of skeletal muscle weakness in adults, in a cross-sectional, retrospective study. In a cohort of 204 adult DM1 patients, we quantified muscle impairment, handgrip force and physical disability. Muscle strength was similarly affected in the legs and in the arms, the right and left side, and distally more than proximally in patients. The earliest and the most affected skeletal muscles were the digit flexors, foot dorsiflexors and neck flexors; whereas the elbow and knee extensors and flexors were the least affected muscle groups. The rate of decline of the muscle strength was −0.111 units/year. The handgrip values were lower in DM1 patients than the normative values and the rate of decline in handgrip force per year was −0.24 kg. Limitation in mobility or walking is observed in 84 % of DM1 patients but requirement of wheelchair is infrequent (3 %). The decrease in muscle strength, handgrip force and the increase in physical disability were highly correlated with duration of the disease and the number of CTG repeats in the blood. Significant association was found between decline in muscle strength and the age at onset, physical disability and the age of patients at evaluation, handgrip force and gender. Decline in muscle weakness is very slow and although limitation when walking is a common manifestation of DM1 in patients, the requirement of wheelchair is infrequent.
Literatur
1.
Zurück zum Zitat Andersen G, Ørngreen MC, Preisler N et al (2013) Muscle phenotype in patients with myotonic dystrophy type 1. Muscle Nerve 47:409–415CrossRefPubMed Andersen G, Ørngreen MC, Preisler N et al (2013) Muscle phenotype in patients with myotonic dystrophy type 1. Muscle Nerve 47:409–415CrossRefPubMed
2.
Zurück zum Zitat Antonini G, Giubilei F, Mammarella A et al (2000) Natural history of cardiac involvement in myotonic dystrophy: correlation with CTG repeats. Neurology 55:1207–1209CrossRefPubMed Antonini G, Giubilei F, Mammarella A et al (2000) Natural history of cardiac involvement in myotonic dystrophy: correlation with CTG repeats. Neurology 55:1207–1209CrossRefPubMed
3.
Zurück zum Zitat Arsenault ME, Prévost C, Lescault A, Laberge C, Puymirat J, Mathieu J (2006) Clinical characteristics of myotonic dystrophy type 1 patients with small CTG expansions. Neurology 25:1248–1250CrossRef Arsenault ME, Prévost C, Lescault A, Laberge C, Puymirat J, Mathieu J (2006) Clinical characteristics of myotonic dystrophy type 1 patients with small CTG expansions. Neurology 25:1248–1250CrossRef
4.
Zurück zum Zitat Birouk N, Gouider R, Le Guern E et al (1997) Charcot-Marie-tooth disease type 1A with 17p11.2 duplication. Clinical and electrophysiological phenotype study and factors influencing disease severity in 119 cases. Brain 120:813–823CrossRefPubMed Birouk N, Gouider R, Le Guern E et al (1997) Charcot-Marie-tooth disease type 1A with 17p11.2 duplication. Clinical and electrophysiological phenotype study and factors influencing disease severity in 119 cases. Brain 120:813–823CrossRefPubMed
5.
Zurück zum Zitat Brook JD, McCurrach ME, Harley HG et al (1992) Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell 68:799–808CrossRefPubMed Brook JD, McCurrach ME, Harley HG et al (1992) Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell 68:799–808CrossRefPubMed
6.
Zurück zum Zitat Cudia P, Bernasconi P, Chiodelli R et al (2009) Risk of arrhythmia in type I myotonic dystrophy: the role of clinical and genetic variables. J Neurol Neurosurg Psychiatry 80:790–793CrossRefPubMed Cudia P, Bernasconi P, Chiodelli R et al (2009) Risk of arrhythmia in type I myotonic dystrophy: the role of clinical and genetic variables. J Neurol Neurosurg Psychiatry 80:790–793CrossRefPubMed
7.
Zurück zum Zitat de Die-Smulders CE, Howeler CJ, Thijs C et al (1998) Age and causes of death in adult-onset myotonic dystrophy. Brain 121:1557–1563CrossRefPubMed de Die-Smulders CE, Howeler CJ, Thijs C et al (1998) Age and causes of death in adult-onset myotonic dystrophy. Brain 121:1557–1563CrossRefPubMed
8.
Zurück zum Zitat Echenne B, Rideau A, Roubertie A, Sebire G, Rivier F, Lemieux B (1998) Myotonic dystrophy type I in childhood: long-term evolution in patients surviving the neonatal period. Eur J Paediatr Neurol 12:210–223CrossRef Echenne B, Rideau A, Roubertie A, Sebire G, Rivier F, Lemieux B (1998) Myotonic dystrophy type I in childhood: long-term evolution in patients surviving the neonatal period. Eur J Paediatr Neurol 12:210–223CrossRef
9.
Zurück zum Zitat Facenda-Lorenzo M, Hernandez-Afonso J, Rodrıguez-Esteban M, de Leon-Hernandez JC, Grillo-Perez JJ (2013) Original cardiac manifestations in myotonic dystrophy type 1 patients followed using a standard protocol in a specialized unit. Rev Esp Cardiol 66:193–197CrossRefPubMed Facenda-Lorenzo M, Hernandez-Afonso J, Rodrıguez-Esteban M, de Leon-Hernandez JC, Grillo-Perez JJ (2013) Original cardiac manifestations in myotonic dystrophy type 1 patients followed using a standard protocol in a specialized unit. Rev Esp Cardiol 66:193–197CrossRefPubMed
10.
Zurück zum Zitat Finsterer J, Gharehbaghi-Schnell E, Stöllberger C, Fheodoroff K, Seiser A (2001) Relation of cardiac abnormalities and CTG-repeat size in myotonic dystrophy. Clin Genet 59:350–355CrossRefPubMed Finsterer J, Gharehbaghi-Schnell E, Stöllberger C, Fheodoroff K, Seiser A (2001) Relation of cardiac abnormalities and CTG-repeat size in myotonic dystrophy. Clin Genet 59:350–355CrossRefPubMed
11.
Zurück zum Zitat Florence JM, Pandya S, King WM et al (1984) Clinical trials in Duchenne dystrophy: standardization and reliability of evaluation procedures. Phys Ther 64:41–45PubMed Florence JM, Pandya S, King WM et al (1984) Clinical trials in Duchenne dystrophy: standardization and reliability of evaluation procedures. Phys Ther 64:41–45PubMed
13.
Zurück zum Zitat Fu YH, Pizzuti A, Fenwick RG Jr et al (1992) An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 255:1256–1258CrossRefPubMed Fu YH, Pizzuti A, Fenwick RG Jr et al (1992) An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 255:1256–1258CrossRefPubMed
14.
Zurück zum Zitat Gharehbaghi-Schnell EB, Finsterer J, Korschineck I, Mamoli B, Binder BR (1998) Genotype-phenotype correlation in myotonic dystrophy. Clin Genet 53:20–26CrossRefPubMed Gharehbaghi-Schnell EB, Finsterer J, Korschineck I, Mamoli B, Binder BR (1998) Genotype-phenotype correlation in myotonic dystrophy. Clin Genet 53:20–26CrossRefPubMed
15.
Zurück zum Zitat Harper PS (2001) Myotonic dystrophy, 3rd edn. Saunders WB, London Harper PS (2001) Myotonic dystrophy, 3rd edn. Saunders WB, London
16.
Zurück zum Zitat Heatwhole C, Bode R, Johnson N et al (2012) Patients-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1). Neurology 79:348–357CrossRef Heatwhole C, Bode R, Johnson N et al (2012) Patients-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1). Neurology 79:348–357CrossRef
17.
Zurück zum Zitat Hébert LJ, Remec JF, Saulnier J, Vial C, Puymirat J (2010) The use of muscle strength assessed with handheld dynamometers as a non-invasive biological marker in myotonic dystrophy type 1 patients: a multicenter study. BMC Musculoskelet Disord 11:72–80PubMedCentralCrossRefPubMed Hébert LJ, Remec JF, Saulnier J, Vial C, Puymirat J (2010) The use of muscle strength assessed with handheld dynamometers as a non-invasive biological marker in myotonic dystrophy type 1 patients: a multicenter study. BMC Musculoskelet Disord 11:72–80PubMedCentralCrossRefPubMed
18.
Zurück zum Zitat Johnson ER, Abresch RT, Carter GT et al (1995) Profile of neuromuscular diseases: myotonic dystrophy. Am J Phys Rehabil 74(suppl 5):S104–S116 Johnson ER, Abresch RT, Carter GT et al (1995) Profile of neuromuscular diseases: myotonic dystrophy. Am J Phys Rehabil 74(suppl 5):S104–S116
19.
Zurück zum Zitat Kaminsky P, Poussel M, Pruna L, Deibener J, Chenuel B, Brembilla-Perrot B (2011) Organ dysfunction and muscular disability in myotonic dystrophy type 1. Medicine 90:262–268CrossRefPubMed Kaminsky P, Poussel M, Pruna L, Deibener J, Chenuel B, Brembilla-Perrot B (2011) Organ dysfunction and muscular disability in myotonic dystrophy type 1. Medicine 90:262–268CrossRefPubMed
20.
Zurück zum Zitat Khoshbakht R, Soltanzadeh A, Zamani B et al (2014) Correlation between distribution of muscle weakness, electrophysiological findings and CTG expansion in myotonic dystrophy. J Clin Neurosci 21:1123–1126CrossRefPubMed Khoshbakht R, Soltanzadeh A, Zamani B et al (2014) Correlation between distribution of muscle weakness, electrophysiological findings and CTG expansion in myotonic dystrophy. J Clin Neurosci 21:1123–1126CrossRefPubMed
21.
Zurück zum Zitat Kierkegaard M, Harms-Ringdahl K, Widén Holmqvist L, Tollbäck A (2009) Perceived functioning and disability in adults with myotonic Dystrophy type 1: a survey according to the international classification of functioning, disability and health. J Rehabil Med 41:512–520CrossRefPubMed Kierkegaard M, Harms-Ringdahl K, Widén Holmqvist L, Tollbäck A (2009) Perceived functioning and disability in adults with myotonic Dystrophy type 1: a survey according to the international classification of functioning, disability and health. J Rehabil Med 41:512–520CrossRefPubMed
22.
Zurück zum Zitat Kole R, Krainer AR, Altman S (2012) RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 11:125–140PubMed Kole R, Krainer AR, Altman S (2012) RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 11:125–140PubMed
23.
Zurück zum Zitat Kroksmark AK, Ekström AB, Björck E, Tulinius M (2005) Myotonic dystrophy: muscle involvement in relation to disease type and size of expanded CTG-repeat sequence. Dev Med Child Neurol 47:478–485CrossRefPubMed Kroksmark AK, Ekström AB, Björck E, Tulinius M (2005) Myotonic dystrophy: muscle involvement in relation to disease type and size of expanded CTG-repeat sequence. Dev Med Child Neurol 47:478–485CrossRefPubMed
24.
Zurück zum Zitat Laberge L, Veillette S, Mathieu J, Auclair J, Perron M (2007) The correlation of CTG repeat length with material and social deprivation in myotonic dystrophy. Clin Genet 71:59–66CrossRefPubMed Laberge L, Veillette S, Mathieu J, Auclair J, Perron M (2007) The correlation of CTG repeat length with material and social deprivation in myotonic dystrophy. Clin Genet 71:59–66CrossRefPubMed
25.
Zurück zum Zitat Magaña JJ, Cisneros B (2011) Perspectives on gene therapy in myotonic dystrophy type 1. J Neurosci Res 89:275–285CrossRefPubMed Magaña JJ, Cisneros B (2011) Perspectives on gene therapy in myotonic dystrophy type 1. J Neurosci Res 89:275–285CrossRefPubMed
26.
Zurück zum Zitat Mahadevan M, Tsilfidis C, Sabourin L et al (1992) Myotonic dystrophy mutation: an unstable CTG repeat in the 3′ untranslated region of the gene. Science 255:1253–1255CrossRefPubMed Mahadevan M, Tsilfidis C, Sabourin L et al (1992) Myotonic dystrophy mutation: an unstable CTG repeat in the 3′ untranslated region of the gene. Science 255:1253–1255CrossRefPubMed
27.
Zurück zum Zitat Marchini C, Lonigro R, Verriello L, Pellizzari L, Bergonzi P, Damante G (2000) Correlations between individual clinical manifestations and CTG repeat amplification in myotonic dystrophy. Clin Genet 57:74–82CrossRefPubMed Marchini C, Lonigro R, Verriello L, Pellizzari L, Bergonzi P, Damante G (2000) Correlations between individual clinical manifestations and CTG repeat amplification in myotonic dystrophy. Clin Genet 57:74–82CrossRefPubMed
28.
Zurück zum Zitat Mathieu J, DeBraekeleer M, Prevost C (1990) Genealogical reconstruction of myotonic dystrophy in the Saguenay-Lac-Saint-Jean area (Quebec, Canada). Neurology 40:839–842CrossRefPubMed Mathieu J, DeBraekeleer M, Prevost C (1990) Genealogical reconstruction of myotonic dystrophy in the Saguenay-Lac-Saint-Jean area (Quebec, Canada). Neurology 40:839–842CrossRefPubMed
29.
Zurück zum Zitat Mathieu J, Allard P, Potvin L, Prevost C, Begin P (1999) A 10-year study of mortality in a cohort of patients with myotonic dystrophy. Neurology 52:1658–1662CrossRefPubMed Mathieu J, Allard P, Potvin L, Prevost C, Begin P (1999) A 10-year study of mortality in a cohort of patients with myotonic dystrophy. Neurology 52:1658–1662CrossRefPubMed
30.
Zurück zum Zitat Mathieu J, Boivin H, Meunier D, Gaudreault M, Begin P (2001) Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy. Neurology 56:336–340CrossRefPubMed Mathieu J, Boivin H, Meunier D, Gaudreault M, Begin P (2001) Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy. Neurology 56:336–340CrossRefPubMed
31.
Zurück zum Zitat Mathieu J, Boivin H, Richards CL (2003) Quantitative motor assesment in myotonic dystrophy. Can J Neurol Sci 30:129–136PubMed Mathieu J, Boivin H, Richards CL (2003) Quantitative motor assesment in myotonic dystrophy. Can J Neurol Sci 30:129–136PubMed
32.
Zurück zum Zitat Mendell JR, Csimma C, McDonald CM et al (2007) Challenges in drug development for muscle disease: a stakeholders’ meeting. Muscle Nerve 35:8–16CrossRefPubMed Mendell JR, Csimma C, McDonald CM et al (2007) Challenges in drug development for muscle disease: a stakeholders’ meeting. Muscle Nerve 35:8–16CrossRefPubMed
33.
Zurück zum Zitat Peric S, Rakocevic Stojanovic V, Basta I, Peric M, Milicev M, Pavlovic, Lavrnic D (2013) Influence of multisystemic affection on health-related quality of life in patients with myotonic dystrophy type 1. Clin Neurol Neurosurg 115:270–275CrossRefPubMed Peric S, Rakocevic Stojanovic V, Basta I, Peric M, Milicev M, Pavlovic, Lavrnic D (2013) Influence of multisystemic affection on health-related quality of life in patients with myotonic dystrophy type 1. Clin Neurol Neurosurg 115:270–275CrossRefPubMed
34.
Zurück zum Zitat Personius KE, Pandya S, King WM, Tawil R, McDermott MP, the FSH DY group (1994) Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. Phys Ther 74:253–263PubMed Personius KE, Pandya S, King WM, Tawil R, McDermott MP, the FSH DY group (1994) Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. Phys Ther 74:253–263PubMed
35.
Zurück zum Zitat Reardon W, Newcombe R, Fenton I, Sibert J, Harper PS (1993) The natural history of congenital myotonic dystrophy: mortality and long term clinical aspects. Arch Dis Child 68:177–181PubMedCentralCrossRefPubMed Reardon W, Newcombe R, Fenton I, Sibert J, Harper PS (1993) The natural history of congenital myotonic dystrophy: mortality and long term clinical aspects. Arch Dis Child 68:177–181PubMedCentralCrossRefPubMed
36.
Zurück zum Zitat Shy ME, Blake J, Krajewski K et al (2005) Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology 64:1209–1221CrossRefPubMed Shy ME, Blake J, Krajewski K et al (2005) Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology 64:1209–1221CrossRefPubMed
37.
Zurück zum Zitat Thompson R, Schoser B, Monckton DG, Blonsky K, Locmüller H (2009) Patients registries and trial readiness in myotonic dystrophy- Treat-NMD/Marigold International Workshop Report. Neuromuscul Disord 19:860–866CrossRefPubMed Thompson R, Schoser B, Monckton DG, Blonsky K, Locmüller H (2009) Patients registries and trial readiness in myotonic dystrophy- Treat-NMD/Marigold International Workshop Report. Neuromuscul Disord 19:860–866CrossRefPubMed
38.
Zurück zum Zitat Wang W, Liu Q, Wang ZX, Zhang W, Yuan Y (2013) Correlation of muscular impairment rating scale with myopathological changes in myotonic dystrophy type 1. Zhonghua Zhonghua Yi Xue Za ZHI 93:508–511PubMed Wang W, Liu Q, Wang ZX, Zhang W, Yuan Y (2013) Correlation of muscular impairment rating scale with myopathological changes in myotonic dystrophy type 1. Zhonghua Zhonghua Yi Xue Za ZHI 93:508–511PubMed
39.
Zurück zum Zitat Werle S, Goldhahn J, Drerup S, Simmen BR, Sprott H, Herren DB (2009) Age- and gender-specific normative data of grip and pinch strength in a healthy adult Swiss population. J Hand Surg 1:76–84CrossRef Werle S, Goldhahn J, Drerup S, Simmen BR, Sprott H, Herren DB (2009) Age- and gender-specific normative data of grip and pinch strength in a healthy adult Swiss population. J Hand Surg 1:76–84CrossRef
40.
Zurück zum Zitat Wheeler TM, Thornton CA (2007) Myotonic dystrophy: RNA-mediated muscle disease. Curr Opin Neurol 20:572–576CrossRefPubMed Wheeler TM, Thornton CA (2007) Myotonic dystrophy: RNA-mediated muscle disease. Curr Opin Neurol 20:572–576CrossRefPubMed
41.
Zurück zum Zitat Whittaker RG, Ferenczi E, Hilton-Jones D (2006) Myotonic dystrophy: practical issues relating to assessment of strength. J Neurol Neurosurg Psychiatry 77:1282–1283PubMedCentralCrossRefPubMed Whittaker RG, Ferenczi E, Hilton-Jones D (2006) Myotonic dystrophy: practical issues relating to assessment of strength. J Neurol Neurosurg Psychiatry 77:1282–1283PubMedCentralCrossRefPubMed
Metadaten
Titel
Natural history of skeletal muscle involvement in myotonic dystrophy type 1: a retrospective study in 204 cases
verfasst von
Jean-Pierre Bouchard
Louise Cossette
Guillaume Bassez
Jack Puymirat
Publikationsdatum
01.02.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 2/2015
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-014-7570-x

Weitere Artikel der Ausgabe 2/2015

Journal of Neurology 2/2015 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.